利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

118 条记录 (耗时 0.036 秒)

    ENZYMATIC DEINKING PROCESS
    41.
    发明公开
    ENZYMATIC DEINKING PROCESS 失效
    方法酶促脱色。

    公开(公告)号：EP0521999A1

    公开(公告)日：1993-01-13

    申请号：EP91907072.0

    申请日：1991-03-21

    申请人： NOVO NORDISK A/S ,  E & M LAMORT

    发明人： BARET, Jean-Luc, Alain, Guy ,  LECLERC, Marc ,  LAMORT, Jean-Pierre

    IPC分类号： C12S3 ,  C12N9 ,  D21C5

    CPC分类号： C12N9/2437 ,  C12Y302/01004 ,  D21C5/005 ,  D21C5/027 ,  Y02W30/648

    摘要： On peut obtenir un bon désencrage des vieux papiers à consistance élevée en commençant par une réduction en pâte à pH élevé, puis en ajoutant de la cellulase alcaline et en laissant la cellulase agir pendant la réduction en pâte et/ou la macération. L'amélioration du désencrage accroît la blancheur et la propreté (moins de particules d'encre) du papier fabriqué à partir de la pâte traitée après séparation des particules d'encre. Ce traitement à la cellulase permet une meilleure utilisation de machines comme les épaississeurs, ainsi qu'un meilleur égouttage de la pâte pendant la fabrication du papier.

    A process for producing heme proteins
    43.
    发明公开
    A process for producing heme proteins 失效
    Verfahren zur Herstellung von Haemproteinen。

    公开(公告)号：EP0505311A2

    公开(公告)日：1992-09-23

    申请号：EP92610017.3

    申请日：1992-03-20

    申请人： NOVO NORDISK A/S

    发明人： Andersen, Henrik Dalboge ,  Jensen, Ejner Bech ,  Welinder, Karen Gjesing

    IPC分类号： C12N15/12 ,  C12N15/80 ,  C12P21/02 ,  C12N9/08 ,  C12N1/14

    CPC分类号： C12N9/0065 ,  C07K2319/02 ,  C12N15/80

    摘要： Heterologous heme proteins may be produced extracellularly in filamentous fungi by transforming a filamentous fungus with a vector comprising a DNA sequence encoding a heterologous heme protein and a DNA sequence encoding a preregion permitting secretion of the expressed heme protein, and culturing the transformed filamentous fungus in a suitable culture medium to produce the heme protein.

    摘要翻译： 通过用包含编码异源血红素蛋白的DNA序列的载体和编码允许分泌所表达的血红素蛋白的前体的DNA序列转化丝状真菌，可以在丝状真菌中细胞外产生异源血红素蛋白，并将转化的丝状真菌 合适的培养基产生血红素蛋白。

    VITAMIN D ANALOGUES, COMPOSITIONS COMPRISING SAID ANALOGUES AND THEIR USE
    48.
    发明授权
    VITAMIN D ANALOGUES, COMPOSITIONS COMPRISING SAID ANALOGUES AND THEIR USE 有权
    维生素D类似物，包含类似物的组合物及其用途

    公开(公告)号：EP1556345B1

    公开(公告)日：2010-12-15

    申请号：EP03757738.4

    申请日：2003-10-23

    申请人： LEO PHARMA A/S

    发明人： BINDERUP, Ernst, Torndal ,  HANSEN, Kai, Holst ,  BRETTING, Claus, Aage, Svensgaard ,  CALVERLEY, Martin, John

    IPC分类号： C07C401/00 ,  A61K31/59 ,  A61P5/20

    CPC分类号： C07C401/00 ,  A61K31/59 ,  A61K31/593

    摘要： Compounds according to formula I: in which formula R1 and R2, which may be the same or different, represent halogen, (C1-C6) hydrocarbyl, optionally substituted with one or two hydroxyl group on one or more fluorine atoms, or, together with the carbon atom to which they are both attached, R1 and R2 form a (C3-C6)carbocyclic ring, or one of R1 and R2 taken together with R3 forms a direct bond, such that a triple bond is constituted, or R1 and R2 represent both hydrogen; R3 when not forming a direct bond with one of R1 and R2 represents hydrogen or (C1-C3)hydrocarbyl; X represents (E)-ethylene, (Z)-ethylene, ethynylene, or a bond; Y and Z independently represent hydrogen or methyl; the bond between C#16 and C#17 is depicted with a dotted line to illustrate that said bond may be either a single bond, in which case the projection of the ring substituents is beta, or a double bond; A represents hydroxyl, fluorine or hydrogen; B represents CH2 or H2; the configuration is the 3-position corresponds to the same configuration as in natural vitamine D3 (normal), or the configuration in the configuration in the 3-position is opposite to that of natural vitamin D3(epi); with the proviso that when X represents (E)-ethylene or (Z)-ethylene, one of R1 and R2 taken together with R3 may not form a direct bond, such that a triple bond is constituted; with the further proviso that when X represents a bond R1 ands R2 are nor hydrogen; with the further proviso that the compound of formula I is not 3(S)-hyroxy-9, 10-secocholesta-5(Z),7(E),10(19),22(E),24-penta-ene; and prodrugs and stereo isomeric forms thereof are provided together with their use in therapy, and their use in the manufacture of medicaments.